Axe Compute Inc. (AGPU) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Axe Compute Inc. has executed a strategic pivot from its legacy oncology drug discovery business to a dual focus on GPU Compute Services and a Digital Asset Treasury Strategy centered on the Aethir (ATH) token. The company operates as a smaller reporting company and is not an emerging growth company. As of May 11, 2026, there were 10,404,641 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $35,311 | $110,310 |
| Net Loss | $(7,708,943) | $(2,442,873) |
| Operating Loss | $(7,728,681) | $(2,287,047) |
| Cash and Cash Equivalents | $6,925,244 | $3,087,588 |
| Digital Assets (ATH) | $20,233,245 | N/A (Strategy adopted late 2025) |
| Total Assets | $45,222,576 | $52,888,346 |
| Total Liabilities | $4,951,816 | $5,171,391 |
| Working Capital | $33,365,078 | $38,503,051 |
| Loss Per Share (Basic/Diluted) | $(0.36) | $(5.12) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by approximately 68% to $35,311, driven by reduced activity in the legacy Drug Discovery Services segment. The new Compute Services segment generated only $6,935 in revenue.
- Significant Digital Asset Loss: The company recorded a $4.3 million loss on digital assets due to the depreciation in the fair value of its ATH holdings. This line item did not exist in the prior year.
- Increased Operating Expenses: General and Administrative (G&A) expenses rose by $1.08 million to $2.9 million, primarily due to severance for the former CEO and increased payroll/stock-based compensation.
- Cash Flow: Net cash used in operating activities increased to $3.7 million (from $0.98 million in Q1 2025) due to higher operating expenses and working capital payments. However, cash balances increased significantly from the prior year due to capital raises in late 2025.
- Discontinued Operations: The Eagan business segment was fully disposed of in Q1 2025; Q1 2026 reflects no discontinued operations activity.
Guidance, Outlook, and Risks
- Treasury Strategy: The company holds approximately 2.83 billion ATH tokens. Management intends to stake these tokens to earn yield and may sell holdings to fund operations. The strategy exposes the company to high volatility in the ATH token price.
- Liquidity: Management believes current cash ($6.9M) and digital assets ($20.2M) are sufficient for the next 12 months. Additional liquidity is available via an At-The-Market (ATM) facility ($18.3M remaining) and a Standby Equity Purchase Agreement (SEPA) with Yorkville ($10M capacity).
- Major Contract: In a subsequent event (April 22, 2026), the company announced a $260 million, 36-month enterprise contract to provide 2,304 NVIDIA B300 GPUs. Deployment is targeted for Q3 2026.
- Management Changes: Significant leadership turnover occurred in Q1 and subsequent to the quarter, including the appointment of a new President (Kyle Okamoto) and Co-CFO (Jeremy Yaukey-Witter), and the resignation of the former CFO.
- Risks: Primary risks include the volatility of the ATH token, the success of the new GPU compute business model, and the potential sale of the legacy drug discovery business (currently under strategic review).
Investor Verification Checklist
- ATH Token Valuation: Verify the current market price of the Aethir (ATH) token and its impact on the $20.2M asset valuation and potential future unrealized losses.
- Contract Execution: Monitor the deployment timeline and revenue recognition schedule for the $260M GPU contract announced in April 2026.
- Legacy Business Disposition: Track the status of the strategic review for the oncology drug discovery segment to determine if a sale or wind-down will occur.
- Cash Burn Rate: Assess the sustainability of the $3.7M quarterly operating cash burn against the $6.9M cash balance and the volatility of the ATH treasury.
- Equity Dilution: Review the terms of the ATM and SEPA facilities, as well as the significant number of pre-funded warrants (14.7M) outstanding, which are included in diluted share counts.